Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As emphasized in the press release we put out this morning, we continue to make significant headway with the development of our pipeline assets, particularly with our first-in-class ophthalmic gene therapy programs, and I'm proud of the momentum we have achieved to-date |
| Our R&D team's dedication and hard work has yielded significant progress and compelling results for our first-in-class modifier gene therapy OCU400 program for RP and LCA patients |
| To recap, what we know from our findings to-date is that OCU400 has a favorable safety and tolerability profile in patients |
| Based on this data, we are highly enthusiastic about the future of OCU400 and the vision-saving potential it may provide to RP and LCA patients |
| From a competitive standpoint, we believe OCU410 is differentiated among other therapies available and in development for geographic atrophy and dry AMD by its frequency of administration, one-time versus multiple injections per year, reduced side effects from structural impact, strong safety profile, its mechanism for restoring homeostasis and preserving the conditions that promote self-help |
| We believe we have strong clinical evidence to initiate our Phase 3 clinical trial in retinitis pigmentosa, RP, patients in early 2024 based on FDA conference |
| OCU410 delivery and preclinical studies of Stargardt disease demonstrated a structural and functional improvement |
| All these catalysts considered, we can safely reiterate that 2024 will be transformative for Ocugen |
| Following additional positive and encouraging clinical study results from our novel modifier gene therapy based Phase 1/2 OCU400 study in September 2023 |
| Shankar Musunuri In closing, I'd like to reiterate our unwavering commitment to groundbreaking science and clinical innovations in order to create effective and positively impactful therapies that are accessible to patients globally |
| Positive trends are observed in all set visual [Indiscernible] instability and improvement factors, which details that 83% of subjects demonstrated stabilization or improvement in the treated eye either on BCVA,LLVA or MLNT scores from baseline |
| This initiative is a testament to the fact that COVID-19 is still rampant with emergence of new variants and needs more durable vaccines to treat them |
| In preclinical studies, OCU410 demonstrated efficacy in regulating multiple pathways involved with the disease, including lipid metabolism, reducing drusen inflammation, regulation of inflammation, suppressing information, oxidative stress, improving cell survival, membrane attack complex -- complement, restoring anti-complement protein |
| We believe the inhaled route of administration has the potential to be the holy grail for broad and durable protection from severe diseases and can suppress the transmission rate |
| As we continue to execute stated plans, we remain focused on delivering long-term value for our shareholders, who have supported us and for prospects of Quant's seeking to be part of our story |
| Sounds great |
| Thank you and have a great day |
| Utilizing a dual-track strategy, we also intend to expand our OCU400 Phase 3 trial in the second-half of 2024 to include patients with Leber Congenital Amaurosis LCA, contingent upon favorable results from the Phase 1/2 study |
| In a recent Harris Poll, we favorably found that 66% of Americans would prefer to have more vaccine options |
| In line with NIAID's missions to support innovation and public health, we look forward to potentially expanding the platform to the flu and other respiratory viral diseases and infections |
| 86% of RHO mutation subjects experienced either stabilization or improvement in MLMT scores from baseline, among which 29% demonstrated three lux luminescence level improvement, demonstrating the gene agnostic mechanism of action of OCU400 |
| Tiffany Hamilton Thanks everyone |
| Congrats on the progress |
| With enrollment begun for our OCU410 and OCU410ST programs, we are diligently working to those patients this quarter |
| Statement |
|---|
| Net loss was approximately $14.2 million or $0.06 net loss per share for the quarter ended September 30, 2023, compared to a net loss of approximately $21.9 million or $0.10 net loss per share for the third quarter of 2022 |
| These diseases often lead to sight loss and ultimately blindness |
Please consider a small donation if you think this website provides you with relevant information